Released May 7, 2015, after the close
10-Q filed May 8, 2015, 38 days after period end · 0001019687-15-001815
Q1 2015 · 10-Q
Revenue$5.73M$5.73M −10.8% vs Q1 2014−15.2% vs Q4 2014
Net Income-$2.26M-$2.26M N/M vs Q1 2014N/M vs Q4 2014
EPS Diluted-$0.02-$0.02 N/M vs Q1 2014no prior Q4 2014 on file
Operating Income-$2,206,000N/M
Operating Cash Flow$995,000N/M
Free Cash Flowderived$780,000N/M
Margins · derived
Operating margin-38.5%−28.3 pt vs Q1 2014
Net margin-39.5%−29.4 pt vs Q1 2014
What the release said
The release
Same quarter
| Metric | Q1 2015 | Q1 2014 | Q1 2013 | Q1 2012 |
|---|---|---|---|---|
| Revenue | $5.73M | $6.42M | $6.12M | $6.07M |
| Net Income | -$2.26M | -$649.00K | -$369.00K | -$1.05M |
| EPS Diluted | -$0.02 | -$0.01 | -$0.01 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR